Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports

Aronson, Jeffrey K

doi:10.1586/17512433.2015.1049598

Cited by 3 publications

(3 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the latter is the most important risk factor for DDIs, it is likely that the populational exposure to the risk conveyed by these deleterious drug associations will rise in the future, except if dedicated interventions succeed to constrain it (Guthrie et al, 2015; Stoll and Kopittke, 2015). If the overall impact and health burden represented by DDIs is difficult to assess given the wide heterogeneity of the adverse events they can induce (Lopez-Gonzalez et al, 2009; Aronson, 2015), the populational exposure to the risk of DDIs can conversely be estimated and characterized by identifying codispensings of drug pairs that are contraindicated or discommended, and by describing which of such drug pairs are frequently codispensed despite their concomitant use is advised against.…”

Section: Introductionmentioning

confidence: 99%

Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study

et al. 2019

View full text Add to dashboard Cite

Introduction: Drug interactions could account for 1% of hospitalizations in the general population and 2–5% of hospital admissions in the elderly. However, few data are available on the drugs concerned and the potential severity of the interactions encountered. We thus first aimed to estimate the prevalence of dispensings including drugs Contraindicated or Discommended because of Interactions (CDI codispensings) and to identify the most frequently involved drug pairs. Second, we aimed to investigate whether the frequency of CDI codispensings appeared higher or lower than the expected for the drugs involved. Methods: We carried out a study using a random sample of all drugs dispensings registered in a database of the French Health Insurance System between 2010 and 2015. The distribution of the drugs involved was described considering active principles, detailing the 20 most frequent ones for both contraindicated or discommended codispensings (DCs). To investigate whether the frequency of CDI codispensings appeared higher or lower than the expected for the drugs involved, we developed a specific indicator, the Drug-drug interaction prevalence study-score (DIPS-score), that compares for each drug pair the observed frequency of codispensing to its expected probability. The latter is determined considering the frequencies of dispensings of the individual drugs constituting a pair of interest. Results: We analyzed 6,908,910 dispensings: 13,196 (0.2%) involved contraindicated codispensings (CCs), and 95,410 (1.4%) DCs. For CCS, the most frequently involved drug pair was “bisoprolol+flecainide” ( n = 5,036); four out of five of the most represented pairs involved cardiovascular drugs. For DCS, the most frequently involved drug pair was “ramipril+spironolactone” ( n = 4,741); all of the five most represented pairs involved cardiovascular drugs. The drug pair involved in the CC with the highest score value was “citalopram+hydroxyzine” (DIPS-score: 3.7; 2.9–4.6); that with the lowest score was “clarithromycin+simvastatin” (DIPS-score: 0.2; 0.2–0.3). DIPS-score median value was 0.4 for CCs and 0.6 for DCs. Conclusion: This high prevalence of CDI codispensings enforces the need for further risk-prevention actions regarding drug-drug interactions (DDIs), especially for arrhythmogenic or anti-arrhythmic drugs. In this perspective, the DIPS-score we develop could ease identifying the interactions that are poorly considered by clinicians/pharmacists and targeting interventions.

show abstract

Section: Introductionmentioning

confidence: 99%

Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…39 A specific checklist for reporting suspected drug interactions, the REporting Anecdotal Drug Interactions checklist (READI), based on the PHARMA and ISoP/ISPE guidelines has also been proposed. 40…”

Section: Report Suspected Drug-herb Interactionsmentioning

confidence: 99%

Drug interactions with herbal medicines: mechanisms and implications

Routledge

Bracchi²,

Woods

2021

Adverse Drug Reaction Bulletin

View full text Add to dashboard Cite

Interactions between herbal and conventional medicines can occur by either pharmacodynamic or pharmacokinetic mechanisms, resulting in a reduction or increase in the effects of the conventional medicine. Healthcare professionals (HCPs) should always take a full medicines history, including herbal medicines use as well as other complementary products (e.g., food supplements and other dietary supplements), and be aware that they may sometimes affect the efficacy or safety of other medicines the patient receives. A range of resources are available to inform HCPs and patients/carers about potential drug/herb interactions. HCPs and the public need to be aware of the importance of reporting suspected adverse drug reactions (including suspected interactions) to the appropriate regulatory agency. Finally, further research is necessary to ascertain the clinical impact and mechanisms of such interactions, and how adverse outcomes can be avoided.

show abstract

“…Results from in vitro studies may offer mechanistic insight but may not translate well into clinical practice [ 10 , 20 , 21 , 22 ]. Animal models may offer insight into the role of metabolites in interaction, but these metabolites may not always be applicable to humans and require further clinical confirmation [ 23 ]. Clinical trials are often performed in healthy homogenous adult populations, and sometimes test inappropriate plant parts or inappropriately prepared products [ 10 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

Herb–Drug Interactions: Worlds Intersect with the Patient at the Center

Babos

Heinan²,

Redmond

et al. 2021

Medicines

View full text Add to dashboard Cite

This review examines three bodies of literature related to herb–drug interactions: case reports, clinical studies, evaluations found in six drug interaction checking resources. The aim of the study is to examine the congruity of resources and to assess the degree to which case reports signal for further study. A qualitative review of case reports seeks to determine needs and perspectives of case report authors. Methods: Systematic search of Medline identified clinical studies and case reports of interacting herb–drug combinations. Interacting herb–drug pairs were searched in six drug interaction resources. Case reports were analyzed qualitatively for completeness and to identify underlying themes. Results: Ninety-nine case-report documents detailed 107 cases. Sixty-five clinical studies evaluated 93 mechanisms of interaction relevant to herbs reported in case studies, involving 30 different herbal products; 52.7% of these investigations offered evidence supporting reported reactions. Cohen’s kappa found no agreement between any interaction checker and case report corpus. Case reports often lacked full information. Need for further information, attitudes about herbs and herb use, and strategies to reduce risk from interaction were three primary themes in the case report corpus. Conclusions: Reliable herb–drug information is needed, including open and respectful discussion with patients.

show abstract

Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports

Cited by 3 publications

References 69 publications

Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study

Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study

Drug interactions with herbal medicines: mechanisms and implications

Herb–Drug Interactions: Worlds Intersect with the Patient at the Center

Contact Info

Product

Resources

About